These results suggest that tumor-produced LXR ligands can repress CD8+ cytotoxic activity and lastly that LXR inhibition via SR9243 could be used to promote CD8+ T-cell mediated tumor cell destruction. This evidence concerns the gene CD8A and neoplasm.